Altimmune presents data from phase 2 momentum trial of pemvidutide in obesity during oral presentation at the american diabetes association's 84th scientific sessions

Full analysis of body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat full analysis of body composition data showed class-leading lean mass preservation with 21.9% of weight loss attributable to lean mass and 78.1% attributable to fat
ALT Ratings Summary
ALT Quant Ranking